Clinical trial
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes
NCT00065312 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00065312 |
|---|---|
| Title | An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Non-Insulin-Dependent |
| Intervention type | Drug |
| Interventions | naveglitazar |
| First posted | Jul 22, 2003 |
| Last update posted | Jul 19, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: